Skip to main content

11.07.2017 | Onkologie | Onlineartikel

Anti-angiogenic and immunotherapeutic approaches in mesothelioma

Malignant pleural mesothelioma (MPM) is a rare tumour that is often diagnosed at an advanced stage. Limited efficacy of the available therapies contributes to the generally poor prognosis for MPM patients. Since 2003, the only approved regimen for MPM treatment has been chemotherapy with pemetrexed and cisplatin, with median survival of approximately 12 months [1].

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten